To circumvent the intrinsic and adaptive immune resistance, an MMP-2-sheddable prodrug nanovesicle was thus engineered for tumor-specific co-delivery of multiple regimens including LY, PPa, and a ROS-liable JQ1 prodrug. This evidence concerns the gene MMP2 and neoplasm.